drugset
drugset / Trial / NCT03202927

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

NCT03202927 ↗

Phase 1 Completed 102 enrolled Adello Biologics, LLC Celerion · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will compare treatment emergent incidence rate of ADA between TPI-120 and US licensed Neulasta in normal healthy adult subjects

Timeline

Start
2017-03-25
Primary completion
2018-03-01
Completion
2018-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications

No indication recorded.